FDA converts Pfizer's Xalkori to full approval
This article was originally published in Scrip
Executive Summary
Pfizer has met the FDA's standards to gain full approval of Xalkori (crizotinib) as a treatment for patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).